Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Mise à jour : Il y a 4 ans
Référence : NCT00881530

Femme et Homme

Extrait

The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.


Critère d'inclusion

  • Diabetes Mellitus, Type 2


Liens